Circulatory effects of the ultra-short-acting beta-1 adrenoceptor antagonist landiolol in critically ill patients

Not Applicable

Recruiting

• Conditions: I48.9; I47.1; Atrial fibrillation and atrial flutter, unspecified; Supraventricular tachycardia

• Registration Number: DRKS00025527
• Lead Sponsor: Gemeinschaftsklinikum Mittelrhein gGmbHAkademisches Lehrkrankenhaus der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-04-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Clinical indication for landiolol application as well as CVC system and PiCCO® catheter

Exclusion Criteria

pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of this study is to use landiolol in everyday clinical practice with regard to the circulatory effects examine critically ill patients. The quantitative analysis of the means of a extended cardiovascular monitoring procedure (transpulmonary thermodilution with integrated pulse contour analysis, PiCCO® method) obtained circulatory parameters should be assess effects and safety.